NANOBIOTIX fait le point sur ses activités et publie ses résultats financiers pour le premier semestre 2024
September 18, 2024 16:15 ET
|
Nanobiotix S.A.
NBTXR3 activé par radiothérapie suivi d’un anti-PD-1 a montré un profil de sécurité favorable, un contrôle de la maladie et une réponse tumorale chez les patients naïfs et résistants aux anti-PD-1,...
NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results
September 18, 2024 16:15 ET
|
Nanobiotix S.A.
RT-NBTXR3 followed by anti-PD-1 demonstrated favorable safety profile, disease control and tumor response in patients both naïve and resistant to anti-PD-1, suggesting that NBTXR3 may prime the immune...
Hagens Berman Reminds MacroGenics (MGNX) Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of Sept. 24, 2024
September 18, 2024 15:07 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your losses now. Class Period: Mar. 7,...
The Gross Law Firm Notifies MacroGenics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – MGNX
September 18, 2024 13:21 ET
|
The Gross Law Firm
NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of MacroGenics, Inc. (NASDAQ: MGNX). Shareholders who purchased shares of MGNX during the...
MGNX Deadline in 6 Days: Kessler Topaz Meltzer & Check, LLP Reminds MacroGenics, Inc. (MGNX) Investors of Filing Deadline in Class Action Lawsuit
September 18, 2024 11:41 ET
|
Kessler Topaz Meltzer & Check LLP
RADNOR, Pa., Sept. 18, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the...
Starton Therapeutics Announces Successful Feasibility Demonstration of STAR-LLD Using BD Evolve™ On-Body Injector
September 18, 2024 10:46 ET
|
Starton Therapeutics Inc.
Successful feasibility study underscores compatibility of STAR-LLD using On-body Injector (OBI) technology and Starton’s proprietary low-dose formulation of lenalidomide (LLD)Based on the positive...
Scilex Holding Company Announces the Continuing Support from Endeavor Distribution LLC in the Multi-Year Agreement for Scilex’s Commercial Products and the Satisfaction of FSF 33433 LLC $10 Million Loan
September 18, 2024 09:00 ET
|
Scilex Holding Company
PALO ALTO, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and...
Revolo Announces New Preclinical Data Further Validating Atopic Dermatitis as a Target Indication for ‘1104
September 18, 2024 08:45 ET
|
Revolo Biotherapeutics
Data continues to differentiate ‘1104 as a potential allergic disease treatment that acts upstream in the immune cascade‘1104 reduces key indices of skin inflammation and inflammatory mediators in a...
Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds
September 18, 2024 08:30 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to...
Ketabon To Present Advancements In At-Home Ketamine Therapy For Treatment-Resistant Depression At ECNP Congress 2024
September 18, 2024 08:30 ET
|
HMNC Holding GmbH
MUNICH, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Ketabon GmbH (“Ketabon” or “the Company”), a joint venture between HMNC Brain Health and Develco Pharma, announced today that the Company will present two...